Guidelines for Managing Stability Issues in ANDA Submissions
1) Purpose
The purpose of this Standard Operating Procedure (SOP) is to provide guidance on identifying, investigating, and resolving stability issues in Abbreviated New Drug Application (ANDA) submissions to the United States Food and Drug Administration (US FDA). This SOP ensures that any stability-related issues are adequately addressed to facilitate approval.
2) Scope
This SOP applies to all personnel involved in the preparation, submission, and management of stability data for ANDA submissions to the US FDA.
3) Responsibilities
Stability Testing Team: Responsible for conducting stability studies, collecting data, and identifying potential stability issues.
Quality Assurance (QA) Team: Responsible for reviewing stability data, investigating issues, and ensuring corrective actions are implemented.
Regulatory Affairs Team: Responsible for communicating with the US FDA and providing necessary documentation to address stability concerns.
4) Procedure
4.1 Identification of Stability Issues
4.1.1 Review all stability data
4.1.2 Conduct a thorough investigation to determine the root cause of any identified stability issue, involving cross-functional teams as needed.
4.2 Documentation and Reporting
4.2.1 Document all findings related to the stability issue, including the
4.2.2 Prepare a comprehensive report outlining the stability issue, the investigation conducted, findings, and any proposed or implemented corrective actions.
4.3 Communication with the US FDA
4.3.1 Submit the stability investigation report to the US FDA as part of the ANDA submission package.
4.3.2 Respond promptly to any US FDA queries or requests for additional information regarding the stability issue.
4.3.3 Provide supplementary data or documentation to demonstrate that the stability issue has been resolved or adequately managed.
5) Abbreviations, if any
US FDA: United States Food and Drug Administration
ANDA: Abbreviated New Drug Application
QA: Quality Assurance
OOS: Out-of-Specification
6) Documents, if any
Stability data sheets, stability investigation reports, correspondence with US FDA, corrective action documentation.
7) Reference, if any
US FDA Guidance for Industry: Stability Testing of Drug Substances and Drug Products, CFR Title 21, ICH Guidelines.
8) SOP Version
Version 1.0